VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma

Modern Pathology

Volumn 24, Issue 4, 2011, Pages 571-578

  Von Teichman, Adriana ^a   Compérat, Eva ^b   Behnke, Silvia ^a   Storz, Martina ^a   Moch, Holger ^a   Schraml, Peter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

multilocular cystic renal cell carcinoma; pVHL and PTEN controlled pathways; VHL mutation

Indexed keywords

CARBONATE DEHYDRATASE IX; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR PAX2; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CLEAR CELL CARCINOMA; CLEAR CELL RENAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DYSREGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY CYST; MULTILOCULAR CYSTIC RENAL CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA MUTATIONAL ANALYSIS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PAX2 TRANSCRIPTION FACTOR; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79953329352     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.222     Document Type: Article

References (34)

1. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, 2004.
2. Halat S, Eble JN, Grignon DJ et al. Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol 2010;23:931-936.
3. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal 2008;1:pe30.
4. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010;16:88-98.
5. Frew IJ, Thoma CR, Georgiev S, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBOJ 2008;27:1747-1757.
6. Stayner C, Iglesias DM, Goodyer PR, et al. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 2006;15: 3520-3528. (Pubitemid 44884119)
7. Thoma CR, Frew IJ, Hoerner CR, et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007;9: 588-595. (Pubitemid 46696541)
8. Winyard PJ, Risdon RA, Sams VR, et al. The PAX2 transcription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformations. J Clin Invest 1996;98:451-459. (Pubitemid 26255745)
9. Schraml P, Frew IJ, Thoma CR, et al. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod Pathol 2009;22:31-36.
10. Moch H. Cystic renal tumors: new entities and novel concepts. Adv Anat Pathol 2010;17:209-214.
11. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008;32: 1239-1245.
12. Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol 2009;33: 384-392.
13. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010;7:277-288.
14. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90. (Pubitemid 24232386)
15. Whaley JM, Naglich J, Gelbert L, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 1994;55:1092-1102. (Pubitemid 24355562)
16. Hansen WJ, Ohh M, Moslehi J, et al. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol 2002;22: 1947-1960. (Pubitemid 34175009)
17. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66: 2000-2011.
18. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196:186-193. (Pubitemid 34110900)
19. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 2005;5:57.
20. Akbari M, Hansen MD, Halgunset J, et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 2005;7:36-39. (Pubitemid 40310163)
21. Sieben NL, ter Haar NT, Cornelisse CJ, et al. PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol 2000;31:1414-1419.
22. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-468. (Pubitemid 41039126)
23. Thoma CR, Frew IJ, Krek W. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle 2007;6:1809-1813. (Pubitemid 47327896)
24. Frew IJ, Minola A, Georgiev S, et al. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol 2008;28: 4536-4548. (Pubitemid 351977752)
25. Suzigan S, Lopez-Beltran A, Montironi R, et al. Multilocular cystic renal cell carcinoma: a report of . 45. cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006;125:217-222. (Pubitemid 43167162)
26. Moch H, Sauter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997;28:1255-1259. (Pubitemid 27492824)
27. Moch H, Sauter G, Gasser T, et al. EGF-r gene copy number gains detected by fluorescence in situ hybridization in renal cell carcinoma. J Pathol 1998;184: 424-429. (Pubitemid 28179903)
28. Liang J, Slingerland JM. Multiple roles of the PI3K/ PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
29. Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199. (Pubitemid 129500937)
30. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281-294. (Pubitemid 46123510)
31. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007;25:4757-4764. (Pubitemid 350086478)
32. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008;123:395-400. (Pubitemid 351842025)
33. Ostrom L, Tang MJ, Gruss P, et al. Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol 2000;219:250-258. (Pubitemid 30152603)
34. Luu VD, Boysen G, Struckmann K, et al. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 2009;15: 3297-3304.